The estimated Net Worth of Steven A Ross is at least $1.8 Million dollars as of 10 May 2018. Mr. Ross owns over 81,999 units of Neogenomics stock worth over $1,410,799 and over the last 9 years he sold NEO stock worth over $0. In addition, he makes $394,188 as Chief Information Officer at Neogenomics.
Steven has made over 6 trades of the Neogenomics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 81,999 units of NEO stock worth $514,134 on 10 May 2018.
The largest trade he's ever made was exercising 112,500 units of Neogenomics stock on 20 April 2016 worth over $442,125. On average, Steven trades about 45,648 units every 83 days since 2015. As of 10 May 2018 he still owns at least 86,499 units of Neogenomics stock.
You can see the complete history of Mr. Ross stock trades at the bottom of the page.
Steven A. Ross serves as Chief Information Officer of the Company. Mr. Ross has served as Chief Information Officer since April 2013. Prior to joining the Company, Mr. Ross served as Vice President Technology at Chico’s FAS, Inc. during the period from 2003 to 2013, where he participated in the direction of all information technology resource planning, budgeting, technology associate development coaching and operation initiatives for the $2.5 billion dollar global consumer products company. Prior to that Mr. Ross worked for Zinn Corporation as a Project Director, assisting Target Inc. Mr. Ross has his B.A. from New Mexico State University.
As the Chief Information Officer of Neogenomics, the total compensation of Steven Ross at Neogenomics is $394,188. There are 7 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Steven Ross is 56, he's been the Chief Information Officer of Neogenomics since 2013. There are 14 older and 11 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Steven's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, US 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, and Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: